Biota targets the sniffles
Monday, 11 August, 2008
Melbourne's Biota Holdings (ASX: BTA) has commenced dosing in an early stage trial of BTA798, an orally delivered inhibitor of human rhinovirus (HRV), a major cause of the common cold.
The UK based trial is aimed at evaluating BTA798 as a prophylactic against HRV infection in 200 health volunteers, who will receive a placebo or one of three dose levels before exposure to an experimental rhinovirus infection.
The drug candidate is designed to bind to clefts on the surface of the virus's capsid shell and interfere with attachment to receptors.
Results are expected in April next year.
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
